TY - JOUR
T1 - Re-induction chemotherapy using FLAG–mitoxantrone for adult patients with relapsed acute leukemia
T2 - a single-center experience from United Arab Emirates
AU - Hassan, Inaam Bashir
AU - Kristensen, Jorgen
AU - Al Qawasmeh, Khalid
AU - Alam, Arif
N1 - Funding Information:
This work was supported by grants from Research Affairs, United Arab Emirates University. The authors would like to thank the staff at The National Cancer Registry, and the Medical Record Department, at Tawam Hospital, Al Ain, UAE. The authors would like to thank Mrs. Mary Kutty Jacob and to the medical students, FMHS, UAEU, who participated in the data collection. No relevant conflicts of interest to declare.
Funding Information:
Acknowledgements This work was supported by grants from Research Affairs, United Arab Emirates University. The authors would like to thank the staff at The National Cancer Registry, and the Medical Record Department, at Tawam Hospital, Al Ain, UAE. The authors would like to thank Mrs. Mary Kutty Jacob and to the medical students, FMHS, UAEU, who participated in the data collection.
Publisher Copyright:
© 2018, The Japanese Society of Hematology.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - We studied the outcome of 47 adult patients with relapsed acute leukaemia (AML = 25 and ALL = 22) treated with FLAG–mitoxantrone regimen. Median time to relapse was 10.7 months (range 1.9–27.7). Complete remission (CR2) was 60.1% which was significantly more frequent in ALL compared to AML (P = 0.049). WBC count < 100 × 109/L at initial diagnosis and time to relapse > 1 year were significantly predictor for CR2 in AML (P = 0.005 for both). Induction death was significantly higher in ALL compared to AML (P = 0.039). Median follow-up was 4.0 months (0.9–119.8) for AML and 2.1 months (range 0.6–118.1) for ALL. Nine patients underwent allogeneic stem-cell transplantation (allo-SCT). Estimated overall survival (OS) at 12 and 18 months was 60.5 and 34.6%, respectively, for AML, and 39.9 and 29.9%, respectively, for ALL. For AML patients failure to achieve CR, WBC count at initial diagnosis > 5 × 109/L and poor cytogenetic risk group was significant predictors of poor OS (P = 0.010, P = 0.025, and P = 0.015, respectively). For ALL patients failure to achieve of CR, WBC count at relapse < 5 × 109/L (CR patients) and lack of any type of consolidation therapy were significant predictor of poor OS (P < 0.001, P = 0.008, P = 0.008, respectively).
AB - We studied the outcome of 47 adult patients with relapsed acute leukaemia (AML = 25 and ALL = 22) treated with FLAG–mitoxantrone regimen. Median time to relapse was 10.7 months (range 1.9–27.7). Complete remission (CR2) was 60.1% which was significantly more frequent in ALL compared to AML (P = 0.049). WBC count < 100 × 109/L at initial diagnosis and time to relapse > 1 year were significantly predictor for CR2 in AML (P = 0.005 for both). Induction death was significantly higher in ALL compared to AML (P = 0.039). Median follow-up was 4.0 months (0.9–119.8) for AML and 2.1 months (range 0.6–118.1) for ALL. Nine patients underwent allogeneic stem-cell transplantation (allo-SCT). Estimated overall survival (OS) at 12 and 18 months was 60.5 and 34.6%, respectively, for AML, and 39.9 and 29.9%, respectively, for ALL. For AML patients failure to achieve CR, WBC count at initial diagnosis > 5 × 109/L and poor cytogenetic risk group was significant predictors of poor OS (P = 0.010, P = 0.025, and P = 0.015, respectively). For ALL patients failure to achieve of CR, WBC count at relapse < 5 × 109/L (CR patients) and lack of any type of consolidation therapy were significant predictor of poor OS (P < 0.001, P = 0.008, P = 0.008, respectively).
KW - ALL
KW - AML
KW - FLAG–mitoxantrone
KW - Re-induction
KW - Relapse
UR - http://www.scopus.com/inward/record.url?scp=85049109170&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049109170&partnerID=8YFLogxK
U2 - 10.1007/s12185-018-2478-3
DO - 10.1007/s12185-018-2478-3
M3 - Article
C2 - 29951735
AN - SCOPUS:85049109170
SN - 0925-5710
VL - 108
SP - 390
EP - 401
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 4
ER -